November 3, 2015 The Canadian Securities Exchange (“CSE”) has given conditional approval for the Company to acquire a 90% interest in LeenLife Pharma S.A. and resume trading. Pursuant to the acquisition of LeenLife Pharma S.A., the Company was required to file a comprehensive disclosure document as a Fundamental Change according to the CSE’s Policy Number 8 with a corresponding trading halt on July 8, 2015. The comprehensive Form 2A filing was posted to Disclosure Hall on October 30, 2015. In due course the Company will change its name to “LeenLife Pharma International Inc.” under the Business Corporations Act (British Columbia).
The Company entered into a Share Purchase Agreement dated July 7, 2015 to acquire a 90% interest in LeenLife Pharma S.A. (a Polish private company) (hereinafter referred to as “LeenLife Poland”), which has developed a process to isolate Omega 3 fatty acids from flax seeds. LeenLife Poland is currently engaged in PCT (Patent Cooperation Treaty) proceedings pertaining to granting patents to the following invention: “Health-giving foodstuff containing ethyl esters of fatty acids, namely of linen oil (flax seed oil), and method for obtaining the same”. The application for granting patent protection pertains to countries of the European Union (“EU”), the Russian Federation, Ukraine, Republic of Belarus, People’s Republic of China, Republic of Korea, Japan, Commonwealth of Australia, New Zealand, Republic of South Africa, State of Israel, Federative Republic of Brazil, United States of America and Canada. LeenLife was established in 2013.
The purchase price is comprised of 12,232,788 shares of the Company at a deemed issuance price of $0.1875 per share for an aggregate value of $2,293,648 and $563,0444 in cash consideration due by January 31, 2016 to reimburse the vendors for tax resulting from their disposition of their shares of LeenLife Poland. The post-transaction capital of the Company is 31,366,121. LeenLife Poland shareholders will hold, in the aggregate, 39% of the post-transaction capital of the Company. There is no change of control resulting from this transaction. Securities issued in this transaction will be subject to applicable regulatory escrow requirements. A finder’s fee not exceeding 3% of the equity portion of the transaction will be paid after completion in connection with this transaction to an arm’s length party for sourcing the acquisition.
For more information, please contact: Stan Lis, CEO Tel: 604 764-0518 Email: email@example.com
Neither the Canadian Securities Exchange nor it Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.